Results 11 to 20 of about 3,357,233 (168)

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality [PDF]

Cancer Cell, 2018
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of homologous recombination (HR)-deficient cancers.
Marieke Van De Ven, Haico Van Attikum, Marcel Van Vugt   +2 more
exaly   +11 more sources

Prospects for PARG inhibitors in cancer therapy [PDF]

Journal of Molecular Cell Biology
Abstract Poly(ADP-ribose) glycosylhydrolase (PARG) is an enzyme involved in hydrolyzing the ribose–ribose bonds present in poly(ADP-ribose) (PAR), which are primarily found in the nucleus. Along with poly(ADP-ribose) polymerase, PARG regulates the level of PAR in cells, playing a crucial role in DNA maintenance and repair processes ...
Ji Jing, Zu Ye, Ye Zu
exaly   +4 more sources

CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer

Cell Death Discovery
Chemoresistance contributes to the majority of deaths in women with ovarian cancer (OC). Altered DNA repair and metabolic signaling is implicated in mediating therapeutic resistance.
Ganesh Acharya, Chinnadurai Mani, Naresh Sah, Karunakar Saamarthy, Robert Young, Mark B. Reedy, Robert W. Sobol, Komaraiah Palle   +7 more
doaj   +2 more sources

Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma [PDF]

bioRxiv, 2020
Glioblastoma (GBM) is the most aggressive primary adult brain tumor, with a median survival of approximately 15 months. Despite novel therapeutic approaches, median survival has remained largely unchanged since the standard of care therapy for GBM was ...
H. Hermanowski, Barbara Huebert, C. Aldrighetti, Jenna K. Hurley, D. Quénet   +4 more
semanticscholar   +2 more sources

Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer

Journal for ImmunoTherapy of Cancer
Background Ovarian cancer is the most lethal gynecological malignancy, with limited treatment options after failure of standard therapies. Despite the potential of poly(ADP-ribose) polymerase inhibitors in treating DNA damage response (DDR)-deficient ...
Lorna Rodriguez-Rodriguez, Rui Huang, Mihaela Cristea, Qianqian Zhao, Adrian Kohut, Hua Yu, Mihae Song, Antons Martincuks, Chunyan Zhang, Edward W Wang, Theresa Austria, Yi-Jia Li, Nicole Lugo Santiago, Rosemarie Martinez Borrero, Binghui Shen   +14 more
doaj   +2 more sources

Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury.

Frontiers in Bioscience, 2007
Cumulative evidence has indicated a critical role of poly(ADP-ribose) polymerase-1 activation in ischemic brain damage. Poly(ADP-ribose) glycohydrolase (PARG) is a key enzyme in poly(ADP-ribose) catabolism. Our previous studies showed that PARG inhibitors, gallotannin (GT) and nobotanin B, can profoundly decrease oxidative cell death in vitro. Here, we
Guangwei Wei, Dongmin Wang, Huafei Lu, S. Parmentier, Qing Wang, S. Panter, William H Frey II, W. Ying   +7 more
semanticscholar   +5 more sources

Genomic and biological aspects of resistance to selective poly(ADP‐ribose) glycohydrolase inhibitor PDD00017273 in human colorectal cancer cells

Cancer Reports, 2023
Background Poly(ADP‐ribose) glycohydrolase (PARG) is a key enzyme in poly(ADP‐ribose) (PAR) metabolism and a potential anticancer target. Many drug candidates have been developed to inhibit its enzymatic activity.
Kaede Tsuda, Chinatsu Kurasaka, Yoko Ogino, Akira Sato   +3 more
doaj   +1 more source

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents

Frontiers in Oncology, 2021
BackgroundPoly ADP-ribose glycohydrolase (PARG) is responsible for the catabolism of PARP-synthesized PAR to free ADP-ribose. Inhibition of PARG leads to DNA repair interruption and consequently induces cell death.
Emad Matanes, Emad Matanes, Vanessa M. López-Ozuna, David Octeau, Tahira Baloch, Florentin Racovitan, Amandeep Kaur Dhillon, Roy Kessous, Roy Kessous, Oded Raban, Oded Raban, Liron Kogan, Liron Kogan, Shannon Salvador, Shannon Salvador, Susie Lau, Susie Lau, Walter H. Gotlieb, Walter H. Gotlieb, Amber Yasmeen   +19 more
doaj   +1 more source

Crystallographic and biochemical analysis of the mouse poly(ADP-ribose) glycohydrolase. [PDF]

PLoS ONE, 2014
Protein poly(ADP-ribosyl)ation (PARylation) regulates a number of important cellular processes. Poly(ADP-ribose) glycohydrolase (PARG) is the primary enzyme responsible for hydrolyzing the poly(ADP-ribose) (PAR) polymer in vivo.
Zhizhi Wang, Jean-Philippe Gagné, Guy G Poirier, Wenqing Xu   +3 more
doaj   +1 more source

PARP and PARG inhibitors in cancer treatment [PDF]

Genes & Development, 2020
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying genomic instability through radiotherapy and chemotherapy has been a powerful but nonselective means of killing cancer cells. Precision medicine has revolutionized cancer therapy by putting forth the concept of selective targeting of cancer cells. Poly(ADP-ribose)
openaire   +2 more sources